Modulatory Role of Traditional Chinese Medicine in Gut–Liver and Adipose–Liver Axis Dysfunction in MASLD

医学 中医药 脂肪性肝炎 脂肪肝 脂肪因子 脂肪变性 疾病 传统医学 生物信息学 临床试验 胰岛素抵抗 慢性肝病 肝病 替代医学 胰岛素 糖尿病 药理学 重症监护医学 精密医学 西医 发病机制 胰岛素受体 代谢综合征 脂联素 临床研究 胰岛素敏感性 梅德林
作者
Sampat Singh Tanwar,Seema Sharma
出处
期刊:Pharmacological research [Elsevier BV]
卷期号:18: 100743-100743 被引量:4
标识
DOI:10.1016/j.prmcm.2025.100743
摘要

Introduction Metabolic dysfunction-Associated Steatotic Liver Disease (MASLD) is the most common chronic liver disease worldwide, affecting around 24% of the population, with regional prevalence ranging from 31.8% in the Middle East to 13.5% in Africa (WHO). MASLD encompasses a spectrum from simple steatosis to non-alcoholic steatohepatitis (NASH), fibrosis, cirrhosis, and hepatocellular carcinoma. Its complex pathogenesis involves insulin resistance, obesity, genetic factors, and chronic inflammation, leading to excessive lipid accumulation in hepatocytes. Current Western treatments primarily address symptoms but offer limited efficacy. Traditional Chinese Medicine (TCM) provides a holistic approach focused on restoring Yin-Yang balance and Qi flow, viewing liver dysfunction as related to dampness and Qi stagnation. Modern research supports TCM’s multi-target actions, showing herbal medicines improve gut microbiota, strengthen the intestinal barrier, reduce inflammation, and modulate adipokines and insulin sensitivity. These mechanisms support TCM’s potential systemic efficacy in managing MASLD, integrating traditional theory with modern pharmacology. Methods A systematic literature search was conducted across major databases including PubMed, Scopus, and Web of Science to identify relevant preclinical and clinical studies published up to 2025. The search strategy employed combinations of keywords such as “Metabolic dysfunction-Associated Steatotic Liver Disease (MASLD),” “Traditional Chinese Medicine (TCM),” “gut-liver axis,” “adipose-liver axis,” “herbal medicine,” “gut microbiota,” and “adipokines.” Studies were included if they investigated molecular mechanisms or therapeutic effects of Chinese herbal medicines in MASLD models, particularly focusing on modulation of the gut-liver and adipose tissue-liver axes. Both in vitro and in vivo experimental studies, as well as relevant clinical trials, were considered. Studies were excluded if they were non-English, case reports, reviews without original data, or lacked mechanistic or therapeutic relevance. This approach aimed to ensure a comprehensive and focused synthesis of high-quality evidence supporting the systemic effects of TCM in MASLD. Results Recent studies highlight the gut-liver and adipose-liver axes as key contributors to MASLD progression. Gut dysbiosis alters bile acids, tryptophan catabolites, and BCAAs, where Bacteroides species promote secondary bile acid accumulation, disrupting FXR signaling and causing lipid imbalance and inflammation. Tryptophan-derived indoles impair gut barrier integrity, worsening liver inflammation and fibrosis, while elevated BCAAs associate with insulin resistance and hepatocyte damage. Obesity-induced adipose dysfunction drives MASLD by releasing excess FFAs, activating NF-κB and PPAR-γ pathways, and secreting pro-inflammatory cytokines (TNF-α, IL-6), further impairing insulin sensitivity. Multiple Traditional Chinese Medicine (TCM) formulations show therapeutic potential in preclinical MASLD models by modulating these axes. Si Miao San increased Lactobacillus and Bifidobacterium while reducing Firmicutes and Proteobacteria , improving microbiota balance and reducing liver steatosis. TiaoGanXiaoZhi enhanced intestinal barrier integrity and reduced systemic inflammation. Jiangzhi Capsule inhibited hepatic lipid accumulation by downregulating SREBP pathways. These findings support TCM’s multi-target mechanisms in improving gut microbiota composition, enhancing barrier function, reducing inflammation, and regulating lipid metabolism in MASLD. Discussion This review demonstrates that TCM offers a multi-target approach to MASLD management by modulating critical metabolic and inflammatory pathways, particularly the gut-liver and adipose tissue-liver axes. These mechanisms align with modern pharmacological findings, providing a scientific basis for ancient medical practices. However, clinical evidence remains limited, and standardized, high-quality clinical trials are needed to validate the efficacy and safety of specific herbal interventions. Future research should focus on elucidating precise molecular targets and optimizing formulation strategies to enhance clinical translation of TCM-based treatments for MASLD.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
共享精神的应助被Richard采纳,获得10
1秒前
1秒前
渔舟发布了新的文献求助10
2秒前
小马甲的应助被BAEKHYUNLUCKY采纳,获得10
3秒前
3秒前
豪豪完成签到,获得积分10
3秒前
4秒前
Luxi发布了新的文献求助10
4秒前
dagongren完成签到,获得积分10
5秒前
6秒前
6秒前
6秒前
LIU发布了新的文献求助10
7秒前
传奇3的应助被yhr采纳,获得10
8秒前
wyk完成签到,获得积分10
9秒前
专注的荣轩完成签到,获得积分10
9秒前
deardorff完成签到,获得积分10
11秒前
11秒前
荼蘼发布了新的文献求助10
12秒前
12秒前
COCO发布了新的文献求助10
13秒前
lulu大王完成签到,获得积分10
14秒前
bqys的应助被岳老师采纳,获得10
15秒前
15秒前
顾矜的应助被受伤的无敌采纳,获得10
16秒前
16秒前
ubless607的应助被Run采纳,获得10
16秒前
尼斯湖中的小水怪完成签到 ,获得积分10
16秒前
江大橘完成签到,获得积分10
16秒前
CYY完成签到,获得积分10
16秒前
李慧敏完成签到,获得积分10
18秒前
Luxi完成签到,获得积分10
18秒前
三月完成签到,获得积分10
19秒前
19秒前
20秒前
jjj完成签到,获得积分10
21秒前
21秒前
山复尔尔发布了新的文献求助10
21秒前
reiner完成签到 ,获得积分10
21秒前
shippou完成签到 ,获得积分10
22秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
Resource Recovery Handbook 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8175157
求助须知:如何正确求助?哪些是违规求助? 9566975
关于积分的说明 21789458
捐赠科研通 7769647
什么是DOI,文献DOI怎么找? 3431836
关于科研通互助平台的介绍 2556078
邀请新用户注册赠送积分活动 2477241